Biotech · Private company
AB Science
Track this companyFree. Adds AB Science to your Dealase workspace and tells you when its record changes.
Clinical trials72 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline15
- Best Supportive CarePhase 3 · Indolent Systemic MastocytosisClinicalTrials.gov · fetched Nov 12, 2026
- DacarbazinePhase 3 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- ImatinibPhase 3 · Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MasitinibPhase 3 · Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MasitinibPhase 3 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- MasitinibPhase 3 · Indolent Systemic MastocytosisClinicalTrials.gov · fetched Nov 12, 2026
- Masitinib (4.5)Phase 3 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Masitinib (6.0)Phase 3 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- RiluzolePhase 3 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- SunitinibPhase 3 · Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- AB8939Phase 2 · Acute Myeloid Leukemia RefractoryClinicalTrials.gov · fetched Nov 12, 2026
- Best supportive carePhase 2 · Mast Cell Activation SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Masitinib 4.5 mg/kg/dayPhase 2 · Mast Cell Activation SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Masitinib 6.0 mg/kg/dayPhase 2 · Mast Cell Activation SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 2 · Acute Myeloid Leukemia RefractoryClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Masitinib for the Treatment of Severe Mast Cell Activation SyndromePHASE2 · UNKNOWN · started Jul 1, 2022ClinicalTrials.gov NCT05449444 · fetched Nov 12, 2026
- AB8939 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPHASE1_PHASE2 · RECRUITING · started Jun 1, 2022ClinicalTrials.gov NCT05211570 · fetched Nov 12, 2026
- Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsPHASE3 · RECRUITING · started Feb 2, 2021ClinicalTrials.gov NCT03127267 · fetched Nov 12, 2026
- Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With ImatinibPHASE3 · COMPLETED · started Apr 1, 2012ClinicalTrials.gov NCT01694277 · fetched Nov 12, 2026
- Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-KitPHASE3 · TERMINATED · started Jan 1, 2011ClinicalTrials.gov NCT01280565 · fetched Nov 12, 2026
- Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)PHASE3 · TERMINATED · started Jan 1, 2009ClinicalTrials.gov NCT00812240 · fetched Nov 12, 2026
- Masitinib in Severe Indolent or Smoldering Systemic MastocytosisPHASE3 · COMPLETED · started Dec 1, 2008ClinicalTrials.gov NCT00814073 · fetched Nov 12, 2026